Citations

Clear

3042 citation(s) found for "Kumar, S".

Trends in survival of patients with primary plasma cell leukemia: A population-based analysis from 1973 to 2010.
Lacy, Martha Q. , Gupta, Vinay , Kapoor, Prashant , Lust, John A., Hayman, Suzanne R. , Zeldenrust, Steven R., Kyle, Robert A. , Kumar, Shaji , Gonsalves, Wilson I. , Rajkumar, S. Vincent , Go, Ronald S. , Dispenzieri, Angela , Singh, Preet Paul , Buadi, Francis K. , Dingli, David , Lin, Yi , Gertz, Morie A.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8608-8608

10.1200/jco.2014.32.15_suppl.8608 Get It

Outcomes after relapse from first autologous stem cell transplantation in multiple myeloma.
Lacy, Martha Q. , Hayman, Suzanne R. , Kapoor, Prashant , Kumar, Shaji , Gonsalves, Wilson I. , Gertz, Morie A. , Dispenzieri, Angela , Gupta, Vinay Kumar , Singh, Preet Paul , Buadi, Francis K. , Dingli, David , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8598-8598

10.1200/jco.2014.32.15_suppl.8598 Get It

ECOG multiple myeloma (MM) clinical trial (CT) accrual performance evaluation utilizing the NCI–Trial Complexity and Elements Scoring (NCI-TCES) and the NCI Myeloma Steering Committee Accrual Working Group (NCI MYSC AWG) scoring models.
Weiss, Matthias , Jacobus, Susanna , Munshi, Nikhil C. , Kumar, Shaji , Lacy, Martha Q. , Stewart, A. Keith, Friedenberg, William R., Kyle, Robert A. , Greipp, Philip R., Gertz, Morie A. , Lonial, Sagar , Fonseca, Rafaël , Dispenzieri, Angela , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8600-8600

10.1200/jco.2014.32.15_suppl.8600 Get It

Free light chain assay and cytogenetic abnormalities for identification of high-risk smoldering myeloma.
Larsen, Jeremy T. , Kumar, Shaji , Esplin, Brandt L., Morice, William G. , Kyle, Robert A. , Gonsalves, Wilson I. , Gupta, Vinay Kumar , Ketterling, Rhett P. , Morice, William George , Dispenzieri, Angela , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8595-8595

10.1200/jco.2014.32.15_suppl.8595 Get It

An open label phase 1b/2 trial of TRC105 and sorafenib in patient with advanced/metastatic hepatocellular carcinoma (HCC) (NCT01806064).
Mody, Kabir , Greten, Tim F. , Simpson, Brian E, Adams, Bonne J., Theuer, Charles P. , Greten, Tim F , Raghav, Kanwal , Paluri, Ravi Kumar , Lee, Richard T. , Kaseb, Ahmed O

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 301-301

10.1200/jco.2018.36.4_suppl.301 Get It

301 Background: Endoglin plays a critical role in angiogenesis and is implicated in resistance to VEGF inhibition. TRC105, an endoglin antibody potentiates anti-tumor activity of sorafenib (S) in preclinical HCC models. The combination of TRC105 and S demonstrated encouraging evidence of activity, including a 33% partial response rate (5/15 pts) by RECIST, at RP2D doses of TRC105 in HCC ( Clin Can Res 2017). Adverse events characteristic of each drug were not increased in frequency or severity when the two drugs were administered concurrently, and most commonly included epistaxis, fatigue, headache and anemia. Methods: Following dose escalation, 21 pts will be enrolled at the RP2D. Four objective responses are required to reject the null hypothesis that the true response rate probability is < 5% with an alpha level of 0.1 and 80% power. Secondary endpoints: DR, PFS, frequency and severity of AEs, PK, immunogenicity, angiogenic biomarkers. Key inclusion criteria: disease not amendable to surgical or local therapies, ECOG ≤ 1; Child-Pugh A or B (7 points) classification. Results: Four pts have been enrolled in phase 1b at TRC105 10 mg/kg (n=4) weekly for four doses and 15 mg/kg every other week thereafter + S 800 mg daily without DLT. One of 3 evaluable pts achieved PR (41% reduction), ongoing at month 4. Serum levels of TRC105 exceeded the target concentration following 4 weekly doses of TRC105 at 10 mg/kg (mean = 59 µg/ml, range 43-80). Mean trough concentration decreased following every other week dosing (mean = 21 µg/ml, range 17-31). Common TRC105 related AEs included ≤ G2 epistaxis and G1 headache. Common S related AEs included G3 hand foot syndrome, ≤G3 periodontal disease, G2 hypertension, ≤G2 increased lipase, ≤G2 fatigue and G1 epistaxis. Conclusions: TRC105 dosed by a hybrid schedule of 10 mg/kg weekly for four doses followed by every other week dosing at 15 mg/kg was tolerable and did not potentiate the toxicity of S. The combination of TRC105 + S demonstrated additional signs of activity, including a PR in 1/3 evaluable pts. 21 pts will be enrolled at the RP2D to assess the primary endpoint of ORR by RECIST. Clinical trial information: NCT01806064.
Factors at de novo donor‐specific antibody initial detection associated with allograft loss: a multicenter study
Schinstock, Carrie A. , Dadhania, Darshana M. , Everly, Matthew J. , Smith, Byron H. , Gandhi, Manish J. , Farkash, Evan A. , Samaniego, Milagros , Stegall, Mark D. , Smith, Byron , Gandhi, Manish, Stegall, Mark D , Schinstock, Carrie , Sharma, Vijay Kumar , Samaniego-Picota, Milagros

Mayo Clinic

Transplant International | December 31, 2018 | Volume: 32 | Issue: 5 | Pages: 502-515

10.1111/tri.13395 | PMID 30597643 Get It

Cerebral Artery Vasospasm Detection Using Transcranial Doppler Signal Analysis
Elzaafarany, Khaled , Kumar, Gyanendra , Nakhmani, Arie , Nakhmani, Arie , Aly, Moustafa H.

Mayo Clinic

Journal of Ultrasound in Medicine | December 29, 2018 | Volume: 38 | Issue: 8 | Pages: 2191-2202

10.1002/jum.14916 | PMID 30593699 Get It

ObjectivesSilent cerebral artery vasospasm in aneurysmal subarachnoid hemorrhage causes serious complications such as cerebral ischemia and death. A transcranial Doppler (TCD) ultrasound system is a noninvasive device that can effectively detect cerebral artery vasospasm as soon as it sets in, even before and in the absence of clinical deterioration. Continuous or even daily TCD monitoring is challenging because of the operator expertise and certification required in the form of a trained sonographer and interpretive experience required in the form of an additionally trained and certified physician to perform these studies. This barrier exists because of a lack of automation for detection (without human intervention) of cerebral artery vasospasm using TCD ultrasound. To overcome this barrier, we present an algorithm that automates detection of cerebral artery vasospasm.MethodsWe extracted features such as the energy, energy entropy, zero‐crossing rate, spectral centroid, spectral speed, spectral entropy, spectral flux, spectral roll‐off, harmonic ratio, chroma, and Mel frequency cepstral coefficients for signal classification. Then we applied principal component analysis to reduce the data dimensionality.ResultsAll of the chosen features were used for training a decision‐tree classifier. The algorithm had high accuracy for cerebral artery vasospasm detection, with overall sensitivity of 87.5% and specificity of 89.74%.ConclusionsThe algorithm has the potential for development into a continuous cerebral artery vasospasm monitor.
Transcranial Doppler Evaluation in Takayasu Arteritis With Oculo-Cerebrovascular Complications
Christiansen, Michael E., O’Carroll, Cumara B. , Kumar, Gyanendra , Larsen, Brandon T. , Dumitrașcu, Oana

Mayo Clinic

The Neurologist | December 29, 2018 | Volume: 24 | Issue: 1 | Pages: 17-21

10.1097/nrl.0000000000000202 | PMID 30586029 Get It

Introduction: Takayasu arteritis is a large-vessel vasculitis that may cause oculo-cerebral ischemia. We report a patient with visual loss as initial manifestation, and discuss transcranial Doppler (TCD) findings before and after surgical revascularization. Case Description: A 19-year-old female developed episodes of transient positional right vision loss, progressing to permanent right vision loss and bright light-induced left amaurosis. Examination demonstrated subclavian bruits, palpable epigastrium aortic pulsation, faint radial pulses, right retinal pallor, arteriolar narrowing, and bilateral boxcarring. Head and neck computed tomography angiogram demonstrated left subclavian origin and right common carotid artery occlusion, and severe innominate and left common carotid artery stenosis. TCD demonstrated right ophthalmic artery flow reversal and nonpulsatile waveforms with dampened spectra in the right anterior circulation. Corticosteroids, methotrexate, infliximab, and dual-antiplatelet therapy were initiated. Eleven weeks later, the patient underwent ascending aortic aneurysm repair and bilateral carotid artery bypass with an aortic graft. Pathology was consistent with chronic active Takayasu arteritis. Two weeks postoperatively, left eye visual symptoms resolved; right visual loss persisted. Postoperative TCD showed marked improvement in cerebral perfusion. Conclusions: Retinal ischemia in young women should prompt emergent inflammatory and systemic vascular evaluation. In our subject, prolonged right retinal ischemia had dismal prognosis despite carotid-aortic revascularization, whereas left retinal boxcarring reversed. Surgical revascularization is recommended for severely symptomatic oculo-cerebrovascular disease, once inflammation is better controlled with immunosuppressive therapy. TCD documented the presence and monitored the subsequent resolution of blood flow changes causing retinal and brain hypoxia.
Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi‐parametric flow cytometry method
Sidana, Surbhi , Jevremović, Dragan , Tandon, Nidhi , Gertz, Morie A. , Greipp, Patricia T. , Lacy, Martha Q. , Morice, William G. , Hanson, Curtis A. , Timm, Michael, Dingli, David , Hayman, Suzanne R. , Kapoor, Prashant , Kyle, Robert A. , Lust, John A., Kumar, Shaji , Tandon, Nidhi , Gertz, Morie A , Buadi, Francis K. , Morice, William, Hanson, Curtis, Gonsalves, Wilson , Leung, Nelson , Go, Ronald S , Rajkumar, S Vincent , Kumar, Shaji K , Jevremovic, Dragan , Sidana, Surbhi , Dingli, David , Greipp, Patricia T , Ketterling, Rhett P. , Dispenzieri, Angela , Baughn, Linda B. , Morice, William George , Gonsalves, Wilson I. , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent

Mayo Clinic

American Journal of Hematology | December 28, 2018 | Volume: 94 | Issue: 4 | Pages: 424-430

10.1002/ajh.25391 | PMID 30592078 Get It

AbstractTrisomies of odd numbered chromosomes are seen in nearly half of patients with multiple myeloma (MM) and typically correlate with a hyperdiploid state and better overall survival (OS). We compared DNA ploidy of monoclonal plasma cells (as a surrogate for the presence of trisomies) assessed simultaneously by PCPRO (plasma cell proliferative index), a novel method that estimates DNA index by multi‐parametric flow cytometry to fluorescence in situ hybridization (FISH) in 1703 patients with plasma cell disorders. The distribution of ploidy was hyperdiploid: 759 (45%), diploid 765 (45%), hypodiploid: 71 (4%), tetraploid/near‐tetraploid: 108 (6%). FISH identified trisomies in 82% (621/756) of patients with hyperdiploidy by PCPRO and no trisomy by FISH was observed in 88% (730/834) of patients without hyperdiploidy. 95% (795/834) of patients without hyperdiploidy on PCPRO had one or less trisomy by FISH. Sensitivity and specificity of PCPRO for detecting hyperdiploidy was 86% (621/725) and 84% (730/865), respectively. Sensitivity increased to 94% (579/618) for patients with more than one trisomy. Newly diagnosed MM patients with hyperdiploidy on PCPRO (147/275) had better OS compared to nonhyperdiploid patients (median not reached vs 59 months, P = 0.008) and better progression free survival (median: 33 vs 23 months, P = 0.03). Within the hyperdiploidy group, patients with high‐hyperdiploidy (DNA index: 1.19‐1.50) versus those with low‐hyperdiploidy (DNA index: 1.05‐1.18) had superior OS (3 year OS of 88% vs 68% P = 0.03). Ploidy assessment by flow cytometry can provide rapid, valuable prognostic information and also reduces the number of copy number FISH probes required and hence the cost of FISH.
Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing
Kumar, Shaji , Buadi, Francis K. , Rajkumar, S. Vincent

Mayo Clinic

Blood | December 26, 2018 | Volume: 133 | Issue: 7 | Pages: 652-659

10.1182/blood-2018-08-825349 | PMID 30587528 Get It

Abstract The treatment landscape for multiple myeloma has dramatically changed over the past decade with the introduction of several new classes of drugs, which are very effective at controlling the disease for prolonged periods of time, especially when used in multidrug combinations. Prior to the advent of these new agents, peripheral blood autologous stem cell transplantation (ASCT) was the mainstay of therapy for patients who were eligible to undergo the procedure, with deep and durable responses in the majority of patients. Despite the introduction of more effective therapies, ASCT continues to play an important role in overall management of younger patients, where it has been integrated with the other therapeutic approaches to provide maximum benefit. Recent phase 3 trials have once again confirmed the survival benefit associated with ASCT in myeloma. Retrospective studies have also demonstrated the feasibility of using ASCT at the time of first relapse rather than as a component of the initial treatment. Significant geographical variations exist in the use of ASCT, especially between the United States and Europe in terms of its use as part of upfront therapy. Much of these differences are driven by the availability of drugs and drug combinations for initial therapy of myeloma as well as maintenance approaches post-ASCT. It is amply clear from these trials that ASCT will continue to play an important role in management of myeloma and is likely to be used as a platform for enhancing the efficacy of other treatment modalities that are currently in development.